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Abstract
 
Natural killer (NK) cells and interferon (IFN)-
 
 
 
 have been implicated in immune surveillance
against tumor development. Here we show that tumor necrosis factor–related apoptosis-induc-
ing ligand (TRAIL) plays a critical role in the NK cell–mediated and IFN-
 
 
 
–dependent tumor
surveillance. Administration of neutralizing monoclonal antibody against TRAIL promoted tu-
mor development in mice subcutaneously inoculated with a chemical carcinogen methylcholan-
threne (MCA). This protective effect of TRAIL was at least partly mediated by NK cells and to-
tally dependent on IFN-
 
 
 
. In the absence of TRAIL, NK cells, or IFN-
 
 
 
, TRAIL-sensitive
sarcomas preferentially emerged in MCA-inoculated mice. Moreover, development of sponta-
neous tumors in p53
 
 
 
/
 
 
 
 mice was also promoted by neutralization of TRAIL. These results in-
dicated a substantial role of TRAIL as an effector molecule that eliminates developing tumors.
Key words: NK cells • IFN-
 
 
 
 • methylcholanthrene-induced ﬁbrosarcoma • p53 • innate 
immune response
 
Introduction
 
Immune surveillance against tumors is mediated by both
innate and adaptive components of the cellular immunity
(1). The adaptive component mainly consists of CD8
 
 
 
CTLs that recognize tumor antigens presented by MHC
class I molecules on tumor cells. Natural killer (NK) cells
have long been implicated in innate immunity against tu-
mors, especially MHC class I–deficient variants (2, 3). Our
recent studies have substantiated a pivotal role of NK cells
in natural protection from primary tumor development
induced by a chemical carcinogen methylcholanthrene
(MCA)
 
* 
 
and tumor metastasis (4–6). NK cells exert antitu-
mor effects by direct cytotoxicity and by producing IFN-
 
 
 
(7). We recently demonstrated that perforin-mediated cy-
totoxicity and IFN-
 
 
 
 act independently, yet together
mostly account for the NK cell–mediated protection from
MCA-induced sarcoma development and experimental tu-
mor metastasis (8). However, the final effector mechanism
by which IFN-
 
 
 
 inhibits the tumor development and me-
tastasis remains unclear.
IFN-
 
 
 
 is a pleiotropic cytokine that can act on both tu-
mor cells and host immunity (9, 10). IFN-
 
 
 
 directly inhib-
its proliferation of some tumor cells in vitro (11) and indi-
rectly inhibits tumor growth in vivo by suppressing tumor
angiogenesis (12, 13). IFN-
 
 
 
 enhances NK cell cytotoxic-
ity by upregulating the expression of adhesion molecules
and by increasing the sensitivity of tumor cells to perforin-
and Fas ligand (FasL)-mediated cytotoxicity (14, 15). In
addition, we have recently revealed a critical contribution
of TNF-related apoptosis-inducing ligand (TRAIL) to the
IFN-
 
 
 
–dependent NK cell protection from tumor me-
tastasis (16, 17). TRAIL is a type-II membrane protein be-
longing to the TNF family, which preferentially induces
apoptotic cell death in a wide variety of tumor cells but
not in normal cells in vitro (18, 19). Preclinical studies in
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mice and nonhuman primates have shown that administra-
tion of recombinant soluble form of TRAIL could sup-
press the growth of TRAIL-sensitive tumor xenografts
with no apparent systemic toxicity (20, 21). However, a
physiological role of TRAIL in tumor surveillance was
largely unknown. We recently found that murine liver NK
cells constitutively expressed TRAIL in an IFN-
 
 
 
–depen-
dent manner, which was at least partly responsible for nat-
ural antimetastatic function of liver NK cells against
TRAIL-sensitive tumor cells (16). We have also demon-
strated that IFN-
 
 
 
–mediated TRAIL induction on NK
cells plays some role in IFN-
 
 
 
–dependent antimetastatic
effects of IL-12 and 
 
 
 
-galactosylceramide (17). Given that
both NK cells and IFN-
 
 
 
 have also been implicated in nat-
ural protection from primary tumor development, TRAIL
may be responsible for the NK cell–mediated and IFN-
 
 
 
–
dependent mechanism of tumor elimination. To address
this possibility, in the present study, we examined the ef-
fects of neutralizing anti-TRAIL mAb on tumor develop-
ment in mice subcutaneously inoculated with MCA. The
tumor-promoting effect of anti-TRAIL mAb and the pref-
erential emergence of TRAIL-sensitive MCA-induced
sarcomas in anti–TRAIL-treated, NK cell-depleted, or
IFN-
 
 
 
–deficient mice indicated a pivotal role of TRAIL
in NK cell– and IFN-
 
 
 
–mediated immune surveillance
against primary tumor development. A substantial contri-
bution of TRAIL to the immune surveillance against
spontaneous tumor development caused by p53 mutation
was also elucidated.
 
Materials and Methods
 
Mice.
 
Male C57BL/6 (B6) mice at 6–8 wk of age were ob-
tain from Charles River Laboratories and The Walter and Eliza
Hall Institute of Medical Research, Melbourne, Australia. B6
IFN-
 
 
 
–deficient mice were provided by Genentech. B6 p53-
deficient (p53
 
 
 
/
 
 
 
) mice were obtained from The Jackson Labora-
tory and were bred to wild-type B6 mice to generate B6 p53 het-
erozygous (p53
 
 
 
/
 
 
 
) mice. All mice were maintained under
specific pathogen-free conditions and used in accordance with
the institutional guidelines of Juntendo University and Peter
MacCallum Cancer Institute.
 
Fibrosarcoma Induction by MCA.
 
Wild-type, p53
 
 
 
/
 
 
 
, and IFN-
 
 
 
–
deficient B6 mice were inoculated subcutaneously in the hind
flank with 5, 25, 100, or 400 
 
 
 
g of 3-MCA (Sigma-Aldrich) in
0.1 ml maize oil. Some mice were administered intraperito-
neally with anti-TRAIL mAb (N2B2 or N2B1) (300 
 
 
 
g), control
rat IgG2a (300 
 
 
 
g) (R35–95; BD PharMingen), or antiasialo
GM1 (ASGM1) Ab (200 
 
 
 
g) (Wako) every 5 d starting on the
day of MCA inoculation. The neutralizing anti–mouse TRAIL
mAbs (N2B2 and N2B1) were prepared as described previously
(22). Depletion of NK cells by the anti-ASGM1 Ab treatment
was verified by flow cytometry (4, 16). Development of fibrosar-
coma was monitored periodically over the course of 100–200 d.
Tumors 
 
 
 
2 mm in diameter and demonstrating progressive
growth were recorded as positive. Tumor size was measured peri-
odically with a caliper as the product of two perpendicular diam-
eters (cm
 
2
 
) and represented as the mean 
 
 
 
 SD of 3–10 tumor-
bearing mice in each group. All data are representative of 2–3
independent experiments with similar results.
 
Isolation and Culture of MCA-induced Sarcoma Cell Lines.
 
When 100 
 
 
 
g MCA-induced sarcomas or spontaneously devel-
oping subcutaneous tumors in mice had reached a size of 0.5 cm
 
2
 
,
mice were killed and tumors were removed aseptically. Tumors
were cut into small pieces and treated with collagenase (Sigma
type IV) at 37
 
 
 
C for 1 h, clumps were removed, and single cells
were cultured in RPMI1640 medium supplemented with 10%
FCS and 2 mM 
 
L
 
-glutamine. The cells were split with 0.1%
EDTA when they reached confluency. All tumor cell lines were
kept in culture for at least 3 mo. The TRAIL-sensitive MCA-III
and the TRAIL-resistant MCA-IV fibrosarcoma cell lines had
been formerly established from wild-type B6 mice inoculated
with 25 
 
 
 
g MCA and treated with anti-ASGM1 antibody.
 
Subcutaneous Outgrowth of MCA-induced Fibrosarcoma Cell Lines.
 
The indicated numbers of TRAIL-sensitive MCA-III and the
TRAIL-resistant MCA-IV fibrosarcoma cell lines in 0.1 ml PBS
were inoculated subcutaneously in the hind flank of B6 mice.
Some mice were intraperitoneally administered with anti-TRAIL
mAb (N2B2) (250 
 
 
 
g) or control rat IgG2a (250 
 
 
 
g) on day –1,
0, 7, 10, and 14. Tumor size was measured periodically over the
course of 40 d with a caliper as described above and represented
as the mean 
 
  
 
SD of 4–5 mice in each group. All data are repre-
sentative of two to three independent experiments with similar
results.
 
Spontaneous Tumor Development in p53
 
 
 
/
 
 
 
 Mice.
 
p53
 
 
 
/
 
 
 
 B6 mice
were administered intraperitoneally with anti-TRAIL mAb
(N2B2) (300 
 
 
 
g) or control rat IgG2a (300 
 
 
 
g) every 5 d starting
at the 3 wk of age. Spontaneous development of tumor was
monitored periodically by palpation over the course of 24 mo.
Tumors 
 
 
 
5 mm in diameter and demonstrating progressive
growth were recorded as positive, and finally confirmed by post-
mortem examination. Some mice were killed and the developing
tumors were analyzed by histological examination.
 
Cytotoxicity Assay.
 
The susceptibility of tumor cells to TRAIL-
mediated cytotoxicity was examined using mouse TRAIL-trans-
fected 2PK-3 (mTRAIL/2PK-3) or mock-transfected 2PK-3 as
the effector cells at an E/T 
 
  
 
10 by an 8 h 
 
51
 
Cr release assay as
described previously (16). In some experiments, tumor cells were
precultured with 2,000 U (100 ng)/ml of mouse recombinant
IFN-
 
 
 
 (BD PharMingen) for 24 h before the cytotoxic assay.
 
Statistical Analysis.
 
Significant differences in incidence at one
time point were determined by the Fisher’s exact test. Significant
differences in progressive incidence and growth were determined
by the unpaired Mann-Whitney U test. 
 
P
 
 values 
 
 
 
0.05 were
considered significant.
 
Results
 
Contribution of TRAIL to Suppression of MCA-induced Sar-
coma Development.
 
To explore the role of TRAIL in natu-
ral protection from tumor development, we examined the
effect of neutralizing anti-TRAIL mAb on the primary tu-
mor development induced by the chemical carcinogen
MCA. Initially, we employed p53
 
 
 
/
 
 
 
 B6 mice to facilitate
the sarcoma development. Although inoculation of 25 
 
 
 
g
or 100 
 
 
 
g MCA eventually induced fibrosarcomas in all
mice treated with either anti-TRAIL mAb or control Ig, a
significantly accelerated onset of tumor and tumor growth
was observed in the anti-TRAIL mAb-treated mice (
 
P 
 
 
 
0.05; Fig. 1 A). At a high dose of 400 
 
 
 
g MCA, however,
no significant difference was observed. In the second set of 
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experiments, we also examined the effect of anti-TRAIL
mAb on the development of MCA-induced fibrosarcomas
in wild-type B6 mice. As shown in Fig. 1 B, wild-type mice
were more resistant to low-dose MCA and showed a later
onset at high doses of MCA than p53
 
 
 
/
 
 
 
 mice. Remark-
ably, 25 
 
 
 
g MCA induced fibrosarcomas in 8/10 of anti-
TRAIL mAb-treated mice but not (0/10) in control Ig-
treated mice. Although 100 
 
 
 
g MCA eventually induced
fibrosarcomas in 8/10 of either anti-TRAIL mAb- or control
Ig-treated mice, tumor onset was significantly accelerated in
anti-TRAIL mAb-treated mice (
 
P
 
   
 
0.05). At a high dose
of 400 
 
 
 
g MCA, however, no significant difference was ob-
served. Fibrosarcoma induction by MCA was similarly pro-
moted by the administration of another neutralizing anti–
mouse TRAIL mAb, N2B1 (data not shown).
We established fibrosarcoma cell lines from 100 
 
 
 
g
MCA-inoculated and anti-TRAIL mAb or control Ig-
treated p53 
 
 
 
/
 
 
 
 mice or wild-type B6 mice, and analyzed
their susceptibility to TRAIL-mediated cytotoxicity. As
shown in Fig. 2 A, 5/8 of the fibrosarcoma cell lines de-
rived from anti-TRAIL mAb-treated p53 
 
 
 
/
 
 
 
 mice were
susceptible to TRAIL-mediated cytotoxicity, while only
1/8 of those from control Ig-treated p53 
 
 
 
/
 
 
 
 mice were
susceptible. As shown in Fig. 2 B, 3/4 of the fibrosarcoma
cell lines derived from anti-TRAIL mAb-treated wild-type
mice were susceptible to TRAIL-mediated cytotoxicity,
while 1/4 of those from control Ig-treated wild-type mice
was susceptible. These results suggested that the TRAIL-
sensitive fibrosarcoma cells that preferentially emerged in
the anti-TRAIL mAb-treated mice were mostly eliminated
in the control Ig-treated mice. Collectively, the tumor-
promoting effect of anti-TRAIL mAb (Fig. 1) and the
preferential emergence of TRAIL-sensitive tumor cells in
anti-TRAIL mAb-treated mice (Fig. 2) indicated a sub-
stantial contribution of TRAIL to natural protection from
MCA-induced fibrosarcoma development.
 
Contribution of TRAIL to Suppression of Subcutaneous Out-
growth of MCA-induced Fibrosarcoma.
 
To explore the in-
hibitory effect of TRAIL on the outgrowth of MCA-
induced fibrosarcomas, we next examined the effect of
anti-TRAIL mAb on the subcutaneous growth of TRAIL-
sensitive or TRAIL-resistant MCA-induced fibrosarcoma cell
lines, which we formerly established from anti-ASGM1
Ab-treated (NK cell–depleted) B6 mice. As shown in Fig.
3 A, MCA-III was sensitive and MCA-IV was resistant to
TRAIL-mediated cytotoxicity. At the three doses of tumor
cells tested, anti-TRAIL mAb treatment consistently pro-
moted the growth of TRAIL-sensitive MCA-III, although
the growth of TRAIL-resistant MCA-IV was not affected
(Fig. 3 B). These results indicated that the suppressive effect
of TRAIL on tumor outgrowth is primarily determined by
the susceptibility of tumor cells to TRAIL and that the di-
rect cytotoxic activity of TRAIL on the tumor cells is the
primary mechanism of tumor suppressive action.
 
Contribution of TRAIL to NK Cell–mediated and IFN-
 
 
 
-
dependent Tumor Surveillance.
 
We previously demonstrated
that the TRAIL-mediated protection from tumor metasta-
sis was mostly mediated by NK cells expressing TRAIL in
Figure 1. Effect of anti-TRAIL
mAb on development of MCA-
induced fibrosarcoma. p53 /  (A) or
wild-type (B) B6 mice were inocu-
lated subcutaneously in the hind
flank with the indicated amount of
MCA. Mice (n   10 in each group)
were administered intraperitoneally
with anti-TRAIL mAb (circles) or
isotype-matched control rat Ig
(squares) every 5 d, and then ob-
served for sarcoma development
over the course of 100–200 d. Tu-
mor sizes in p53 /  mice were also
recorded over that period and are
represented as the mean   SD of
3–10 mice in each group. 
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an IFN-
 
 
 
–dependent manner (16, 17) and that IFN-
 
 
 
played a substantial role in NK cell–mediated protection
from MCA-induced sarcoma development indepen-
dently of perforin-mediated cytotoxicity (8). To address
the possible contribution of TRAIL to the NK cell–
mediated and IFN-
 
 
 
–dependent protection from tumor
development, we first examined the effect of NK cell de-
pletion by anti-ASGM1 Ab on the tumor-promoting
effect of anti-TRAIL mAb in the MCA model (25 
 
 
 
g).
As shown in Fig. 4 A, the tumor-promoting effect of
anti-ASGM1 Ab was almost equivalent to that of anti-
TRAIL mAb, and the combined treatment with anti-
TRAIL mAb and anti-ASGM1Ab showed an additional
effect (
 
P 
 
 
 
 0.05), suggesting that TRAIL might protect
independently of NK cells. However, MCA-induced fib-
rosarcoma cell lines derived from the NK cell–depleted
mice were more frequently sensitive to TRAIL-mediated
cytotoxicity than those derived from the control Ig-
treated mice (Fig. 5 B), suggesting that TRAIL was in-
volved in the NK cell-mediated surveillance against
MCA-induced sarcoma development. Therefore, in ad-
dition to NK cells, some other effector cells might partic-
ipate in the TRAIL-mediated surveillance against MCA-
induced sarcoma development.
Next, we examined the contribution of TRAIL to IFN-
 
 
 
–dependent tumor surveillance by using IFN-
 
 
 
–deficient
mice in the MCA-induced fibrosarcoma development. As
shown in Fig. 5, the tumor-promoting effect of IFN-  de-
ficiency was equivalent to that of anti-TRAIL mAb in
wild-type mice, and anti-TRAIL mAb did not further pro-
moted the tumor development in IFN- –deficient mice.
In addition, 4/4 of MCA-induced fibrosarcoma cell lines
derived from IFN- –deficient mice were sensitive to
TRAIL-mediated cytotoxicity (Fig. 6). These results indi-
cated that IFN-  was essential for the TRAIL-mediated tu-
mor surveillance and that TRAIL was mostly responsible
Figure 2. Selection of TRAIL-
resistant fibrosarcomas in vivo.
Cell lines were originated from
MCA-induced fibrosarcomas de-
veloped in isotype-matched con-
trol rat Ig- or anti-TRAIL mAb-
treated p53 /  (A) or wild-type (B) B6 mice. Then, their susceptibility to TRAIL-mediated
cytotoxicity was determined by an 8 h 51Cr release assay using mTRAIL-transfected 2PK-3
(mTRAIL-2PK3) and mock-transfected 2PK-3 cells as effector cells. Data are represented as
the mean   SD of triplicate samples at an E/T   10. The cytotoxic activity of mock-trans-
fected 2PK-3 against all tumor cells was  2% (data not shown).
Figure 3. Effect of anti-TRAIL mAb on outgrowth of subcutaneously inoculated fibrosarcoma cell lines. (A) Susceptibility of MCA-induced fibrosar-
coma cell lines to TRAIL-mediated cytotoxicity. Cytotoxic activity of mTRAIL-transfected 2PK-3 (mTRAIL/2PK-3) and mock-transfected 2PK-3
cells against MCA-induced fibrosarcoma cell lines (MCA-III and MCA-IV) was tested by an 8 h 51Cr release assay. Data are represented as the mean  
SD of triplicate samples at an E/T ratio   10. (B) The indicated number of MCA-III (white symbols) and MCA-IV (black symbols) cells were inoculated
subcutaneously in the hind flank of wild-type B6 mice. Mice were administered intraperitoneally with anti-TRAIL mAb (circles) or isotype-matched
control rat Ig (squares) every 5 d. Data are represented as the mean   SD of five mice in each group.165 Takeda et al.
for the IFN- –mediated tumor surveillance against MCA-
induced fibrosarcomas.
We further examined whether IFN-  might affect the
susceptibility of tumor cells to TRAIL-mediated cytotox-
icity, since the IFN-  responsiveness of tumor cells has
been reported to be critical for the IFN- –mediated sur-
veillance against MCA-induced sarcoma (23). As shown
in Fig. 6, pretreatment with IFN-  increased the TRAIL
susceptibility of 3/5 of MCA-induced fibrosarcoma cell
lines derived from anti-TRAIL mAb-treated p53 /  mice
and 2/3 of those from anti-TRAIL mAb-treated wild-
type mice. Moreover, IFN-  enhanced the TRAIL sus-
ceptibility of 4/4 of MCA-induced fibrosarcoma cell lines
from anti-ASGM1 Ab-treated mice and 4/4 of those from
IFN- –deficient mice. In contrast, IFN-  did not sub-
stantially increase the TRAIL susceptibility of MCA-
induced fibrosarcoma cell lines from control Ig-treated
mice, except for MCA-g which was susceptible to TRAIL
without IFN-  treatment. These results suggested that en-
dogenous IFN-  might control the TRAIL-mediated sur-
veillance against MCA-induced fibrosarcomas not only
by upregulating TRAIL expression in effector cells but
also by sensitizing tumor cells to TRAIL-mediated cyto-
toxicity.
Contribution of TRAIL to Suppression of Spontaneous Tumor
Development in p53 /  Mice. To further explore the gen-
eral role of TRAIL in natural protection from primary tu-
mor development in vivo, we finally examined the effect of
neutralizing anti-TRAIL mAb treatment on the spontane-
ous tumor development in p53 /  mice. No tumor devel-
opment was observed before 11 mo of age in both control
Ig-treated and anti-TRAIL mAb-treated p53 /  mice. At
11 mo of age, development of sarcomas was initially ob-
served in anti-TRAIL mAb-treated p53 /  mice, and then
the anti-TRAIL mAb treatment significantly promoted the
tumor development as compared with control Ig-treated
mice until 24 mo of age (P   0.05) (Fig. 7 A). At autopsy,
the tumors mainly consisted of sarcomas and disseminated
lymphomas as previously reported for untreated p53 /  B6
mice (24, 25), and no apparent difference in tumor types
was observed between the anti-TRAIL mAb-treated group
and the control Ig-treated group (data not shown). We es-
tablished sarcoma cell lines from the anti-TRAIL mAb- or
control Ig-treated p53 /  mice, and analyzed their suscep-
tibility to TRAIL-mediated cytotoxicity. As shown in Fig.
7 B, the tumor cell lines derived from anti-TRAIL mAb-
treated p53 /  mice were susceptible to TRAIL-mediated
cytotoxicity, which was augmented by pretreatment with
IFN- , while the tumor cell lines derived from control Ig-
treated p53 /  mice were not susceptible to TRAIL even
Figure 4. Contribution of TRAIL to NK cell–mediated tumor surveil-
lance. (A) p53 /  B6 mice (n   10 in each group) were subcutaneously
inoculated with 25  g MCA and treated with isotype-matched control
rat Ig ( ), anti-TRAIL mAb ( ), anti-ASGM1 Ab ( ), or anti-ASGM1
Ab and anti-TRAIL mAb ( ). Mice were observed for sarcoma develop-
ment over the course of 125 d. (B) Cell lines were originated from MCA-
induced fibrosarcomas developed in control Ig-treated or anti-ASGM1
Ab-treated wild-type B6 mice, and their susceptibility to TRAIL-medi-
ated cytotoxicity was determined as described in Fig. 2. Data are repre-
sented as the mean   SD of triplicate samples at an E/T   10. The cyto-
toxic activity of mock-transfected 2PK-3 cells against all tumor cells was
 2% (data not shown).
Figure 5. Contribution of TRAIL to IFN- –mediated tumor surveil-
lance. Groups of 10 wild-type (circles) and IFN- -deficient (triangles) B6
mice were inoculated subcutaneously with the indicated amount of
MCA, and treated with isotype-matched control rat IgG (white) or anti-
TRAIL mAb (black) as described in Fig. 1. Mice were observed weekly
for sarcoma development over the course of 180 d.166 TRAIL-mediated Immune Surveillance Against Tumor Development
after IFN-  treatment. These results suggested that the
TRAIL-sensitive spontaneously arising tumor cells that
preferentially emerged in the anti-TRAIL mAb-treated
p53 /  mice were mostly eliminated in the control Ig-
treated p53 /  mice, as in the case of MCA-induced fibro-
sarcomas. These results indicated a substantial contribution
of TRAIL to the natural protection from spontaneous tu-
mor development due to the p53 mutation.
Discussion
In this study, we demonstrated that the administration of
neutralizing mAbs against TRAIL promoted MCA-induced
tumor development in p53 /  or wild-type B6 mice and
spontaneous tumor development in p53 /  mice. These
results suggested a substantial role of TRAIL in natural pro-
tection from tumor development. Although potent thera-
peutic effects of soluble recombinant TRAIL against hu-
man tumor xenografts in nude and SCID mice have been
reported (20, 21), this is the first indication that endoge-
nous TRAIL plays a critical role in host surveillance against
primary tumor development in vivo. Consistent with our
present results using neutralizing anti-TRAIL mAbs, we
have recently observed that MCA-induced sarcoma devel-
opment was promoted in TRAIL-deficient B6 mice gener-
ated by gene targeting to just a similar extent to that was
observed in the anti-TRAIL mAb-treated wild-type B6
mice (unpublished data). The contribution of TRAIL to
the suppression of spontaneous tumor development in p53
mutant mice is now to be verified by crossing the TRAIL-
deficient mice with the p53 mutant mice.
Heterogenous tumor cells with different TRAIL sen-
sitivity are expected to arise during the MCA-induced
Figure 6. Effect of IFN-  on susceptibility of MCA-induced fibrosar-
coma cells to TRAIL-mediated cytotoxicity. MCA-induced fibrosarcoma
cells from control Ig- or anti-TRAIL mAb-treated p53 /  or wild-type
mice, control Ig- or anti-ASGM1 Ab-treated wild-type mice, or IFN- –
deficient mice were preincubated with (solid black bars) or without (gray
bars) IFN-  for 24 h. Then, their susceptibility to TRAIL-mediated cy-
totoxicity was determined as described in Fig. 2. Data are represented as
the mean   SD of triplicate samples at an E/T   10. The cytotoxic ac-
tivity of mock-transfected 2PK-3 cells against all tumor cells was  2%
(data not shown).
Figure 7. Effect of anti-TRAIL mAb on spontaneous tumor develop-
ment in p53 /  mice. (A) p53 /  B6 mice were administered intraperito-
neally with anti-TRAIL mAb (circles) or isotype-matched control rat Ig
(squares) every 5 d starting at 3 wk of age, and then observed for tumor
development over the course of 24 mo. Difference between two groups
was statistically significant (P   0.05) as analyzed by unpaired Mann-
Whitney U test. (B) Cell lines were originated from spontaneous sarcoma
development in isotype-matched control rat Ig- or anti-TRAIL mAb-
treated p53 /  mice. Then, their susceptibility to TRAIL-mediated cyto-
toxicity was determined as described in Fig. 2 after the preincubated with
(solid black bars) or without (gray bars) IFN-  for 24 h. Data are repre-
sented as the mean   SD of triplicate samples at an E/T   10. The cyto-
toxic activity of mock-transfected 2PK-3 cells against all tumor cells was
 2% (data not shown).167 Takeda et al.
or spontaneous tumor development in individual mice.
However, the preferential emergence of TRAIL-sensitive
fibrosarcoma cells in the anti-TRAIL mAb-treated mice,
but rarely in the control Ig-treated mice, strongly sug-
gested a selective pressure against TRAIL-sensitive cells
during MCA-induced or spontaneous tumor develop-
ment. Although no obvious TRAIL-mediated suppression
of tumor initiation was observed at overwhelming doses of
MCA (400  g), this may be due to an emergence of too
many transformed cells to be depleted by endogenous
TRAIL. Consistent with a lack of effective selection, fi-
brosarcoma cell lines derived from 400  g MCA-inoculated
mice were more frequently TRAIL-sensitive than those
from 100  g MCA-inoculated mice (data not shown). Al-
though the presented data suggested that the direct cyto-
toxic effect of TRAIL on developing tumor cells is the pri-
mary mechanism for the tumor suppression, immune
responses against tumors might be also affected by the
TRAIL blockade, since it has been reported that TRAIL
may play a regulatory role in some autoimmune disease
models in mice (26, 27).
In the case of MCA-induced sarcoma development, we
previously demonstrated a critical contribution of NK cells
as the effector cells and that of perforin and IFN-  as the
effector mechanism (4, 8). In the present study, the pre-
dominant contribution of TRAIL to IFN- –dependent
protection from tumor development was illustrated in the
MCA-induced fibrosarcoma model. Some dissociation be-
tween the NK cell-mediated protection and the TRAIL-
mediated protection was observed, which may be ex-
plained by the perforin-dependent protection by NK cells
and the possible expression of TRAIL on some effector
cells other than NK cells. It has been shown that TRAIL
was expressed on IFN- –stimulated monocytes and den-
dritic cells in vitro (28, 29). Therefore, these cells may also
participate in the IFN- –dependent and TRAIL-mediated
protection against MCA-induced sarcoma development.
Nevertheless, the preferential emergence of TRAIL-sus-
ceptible fibrosarcomas in the NK cell–depleted mice and
the IFN- –deficient mice strongly supports the contribu-
tion of TRAIL to NK cell– and IFN- –mediated surveil-
lance against MCA-induced fibrosarcomas.
It remains to be determined whether TRAIL also plays a
substantial role in natural protection from primary tumors
induced by chemical carcinogens other than MCA or
spontaneously arising tumors in tumor-prone mice other
than p53 /  mice. Perforin was shown to be critical in
protection from MCA-induced sarcomas, but not that from
12-O-tetradecanoylphorbol-13-acetate plus 7,12-dimeth-
ylbenzanthracene–induced skin papillomas or Moloney
murine sarcoma and leukemia virus-induced sarcomas (30).
We also recently reported a critical role of perforin in sur-
veillance against spontaneous lymphoma, but not sarcoma,
development in p53 /  or p53 /  mice (25). The contri-
bution of TRAIL to IFN- –dependent protection suggests
that tumor models where IFN-  controls tumor develop-
ment are of greatest interest. Notably, IFN-  has been im-
plicated in surveillance against the development of various
nonlymphoid tumors in p53 /  mice (23). However, it
should be noted that the expression of TRAIL receptor 2
(TRAIL-R2), which is the only known TRAIL receptor
in mice (31), has been reported to be regulated by p53 in
human tumor cell lines (32, 33), arguing against the poten-
tial utility of the p53 /  model. To address the general role
of TRAIL in tumor surveillance, further studies are now
underway by using the neutralizing anti-TRAIL mAbs and
the TRAIL-deficient mice.
We have previously demonstrated that IFN-  plays an
essential role in inducing TRAIL expression on NK cells
in vivo (16, 17). IFN-  may also induce TRAIL expres-
sion on monocytes and dendritic cells (28, 29). Our
present results suggested that IFN-  may regulate TRAIL-
mediated tumor surveillance not only by regulating
TRAIL expression on effector cells, but also by sensitizing
tumor cells to TRAIL-mediated cytotoxicity. The mecha-
nism by which IFN-  sensitizes tumor cells to TRAIL re-
mains to be determined. Although two death-inducing
receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) and
two decoy receptors (TRAIL-R3/DcRI and TRAIL-R4/
DcR2) have been identified in humans (34, 35), only one
homologous to TRAIL-R2 has been identified in mice
(31). IFN-  may upregulate the expression of TRAIL-R2
on tumor cells. Alternatively, IFN-  may downregulate
the expression of intracellular Fas-associated death domain-
like IL-1 -converting enzyme-inhibitory proteins (FLIPs)
that protects cells from TRAIL-induced apoptosis (36, 37)
or upregulate the expression of caspases that execute
TRAIL-induced apoptosis (38). It is noteworthy that hu-
man tumor cell lines are more frequently TRAIL-sensitive
than murine tumor cell lines. This may be due to the pres-
ence of decoy receptors in humans, which are expressed on
normal cells and may protect newly transformed cells from
TRAIL-mediated surveillance during tumor development.
Further studies are needed to explore the possible differ-
ence between mice and humans in the role of TRAIL in
tumor surveillance.
Recently, Shankaran et al. demonstrated a critical contri-
bution of IFN-  to immune surveillance against trans-
planted MCA-induced sarcomas in 129/Sv/Ev mice, that
appeared to be mediated by MHC class I–restricted CD8 
CTLs (39). In this model, IFN-  appeared to act predomi-
nantly on tumor cells to upregulate MHC class I and trans-
porter associated protein 1, increasing tumor immunoge-
nicity for adaptive immunity (23, 39). This study is
complementary in demonstrating an additional function of
IFN-  in controlling TRAIL-mediated innate immune
surveillance against tumors. Since the adaptive immunity
against tumors depends on the presence of appropriate tu-
mor antigens, the TRAIL-mediated innate protection may
be more versatile as the natural defense against tumors. Fur-
ther studies on the molecular mechanisms by which IFN- 
and TRAIL contribute to immune surveillance against tu-
mors may provide a novel strategy to prevent tumor devel-
opment in humans.
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